Fatemeh Ghaffarifar

Dr. Fatemeh Ghaffarifar


Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2020 in Comparative Immunology, Microbiology and Infectious Diseases
Verified
Journal Article
Closed access
MFMasoud Foroutan
Masoud Foroutan
FGFatemeh Ghaffarifar
Fatemeh Ghaffarifar
ZSZohreh Sharifi
Zohreh Sharifi
ADAbdolhossein Dalimi
Abdolhossein Dalimi

1 May 2018 in Ultrasonics Sonochemistry
Verified
Journal Article
Open access
RAReza Abazari
Reza Abazari
AMAli Reza Mahjoub
Ali Reza Mahjoub
SMSoheila Molaei
Soheila Molaei
FGFatemeh Ghaffarifar
Fatemeh Ghaffarifar
EGEzatollah Ghasemi
Ezatollah Ghasemi
CCCameron L. Carpenter-Warren
Cameron L. Carpenter-Warren
In this work, a magnetic bio-metal-organic framework (MBMOF) nanocomposite with porous-layer open morphology is synthesized through a simple sonochemical approach and its effects on Leishmania major (MRHO/IR/75/ER) under both in vitro and in vivo conditions are investigated. The effects of sonication time, initial concentration of reagents and sonication power on size and morphology of MBMOF nanocomposites have been investigated and optimized. A comparison was then made between the structural information of the nanostructures and that of the bio-metal-organic framework crystals. Using the powder X-ray diffraction (PXRD), field emission scanning electron microscope (FE-SEM), transmission electron microscopy (TEM), Fourier transform infrared spectroscopy (FTIR), energy dispersive analysis of X-ray (EDAX), vibrating sample magnetometer (VSM), thermogravimetric analysis (TGA), and Brunauer-Emmet-Teller (BET) techniques, the prepared MBMOF nanocomposites were characterized. The mean numbers of promastigotes (cell/ml) in different MBMOF concentrations (3.12, 6.25, 12.5, 25, 50, 100, 200 and 400 µg mL-1) were determined by direct counting after 24, 48 and 72 h. Using MTT assays, the cytotoxic impacts of the MBMOF nanocomposites on promastigotes, intracellular amastigotes, and J774 macrophages were estimated. In order to investigate their therapeutic effects, the prepared MBMOF nanocomposites (25 and 12.5 µg mL-1) were used as ointment three times a week to treat Leishmania major in BALB/c mice. The lesion size and weight of mice were assessed before and during the treatment. The parasitic loads were measured in spleen and liver through the culture. After 72 h, the INF-γ and IL-4 cytokines levels in the supernatant of the spleen culture were measured. To the best of the authors' knowledge, this study is the first to attempt to synthesize the bio-MOFs through an in-situ sonosynthesis route under ultrasound irradiation and examine their cytotoxicity effects on Leishmania major under in vitro and in vivo conditions.

1 January 2018 in Drugs of Today
Verified
Journal Article
Closed access
FGFatemeh Ghaffarifar
Fatemeh Ghaffarifar
DNA vaccines are considered as third-generation vaccines. The recombinant DNA technology plays an important role in the production of DNA vaccines. These vaccines are intended to increase DNA insertion and translation in the cell, activate CD4+ T cells, and enhance cytotoxic T-lymphocyte induction and antibody production. DNA vaccines are safe with few side effects in humans and animals. Their immunogenicity can be improved by the use of suitable adjuvants and proper delivery systems. In recent years, strategies have been developed to increase the efficacy of DNA vaccines through electroporation, as well as the use of cytokines, genetically engineered vectors, liposomes, and micro- or nanoparticles. In the last decade, significant advances have been made in the field of DNA immunization. Strategies such as the use of DNA vaccines in combination with genetic adjuvants and prime-boost immunization increase the protective response and decrease the doses of DNA vaccines. Vaccine efficacy is influenced by the route of immunization, with intracutaneous injection of the plasmid having been found to be more effective than intramuscular or subcutaneous injection even at lower doses. DNA vaccines are useful in both humans and animals against infectious diseases, allergies and even cancer. This review elaborates on the current status of DNA immunization in the medical and veterinary fields.

1 January 2019 in Clinical and Experimental Vaccine Research
Verified
Journal Article
Open access
MFMasoud Foroutan
Masoud Foroutan
FGFatemeh Ghaffarifar
Fatemeh Ghaffarifar
ZSZohreh Sharifi
Zohreh Sharifi
ADAbdolhossein Dalimi
Abdolhossein Dalimi
OJOgholniaz Jorjani
Ogholniaz Jorjani
Foroutan M, et al. Clin Exp Vaccine Res. 2019 Jan;8(1):4-26. https://doi.org/10.7774/cevr.2019.8.1.4

1 August 2018 in Infection, Genetics and Evolution
Verified
Journal Article
Closed access
MFMasoud Foroutan
Masoud Foroutan
FGFatemeh Ghaffarifar
Fatemeh Ghaffarifar
ZSZohreh Sharifi
Zohreh Sharifi
ADAbdolhossein Dalimi
Abdolhossein Dalimi
MPMajid Pirestani
Majid Pirestani

2 October 2020 in Transactions of the Royal Society of Tropical Medicine and Hygiene
Verified
Journal Article
Closed access
PDF file
ATAli Taghipour
Ali Taghipour
SGSahar Ghodsian
Sahar Ghodsian
MJMahdi Jabbari
Mahdi Jabbari
MOMeysam Olfatifar
Meysam Olfatifar
AAAmir Abdoli
Amir Abdoli
FGFatemeh Ghaffarifar
Fatemeh Ghaffarifar
Intestinal parasitic infections (IPIs) during pregnancy, if left untreated, can cause adverse effects for the mothers, foetuses and newborns. However, limited information is available about the global status of IPIs in pregnant women. Here we undertook a meta-analysis to estimate the global prevalence of IPIs and associated risk factors in pregnant women. We searched the PubMed, Science Direct, Scopus, Web of Science and Google Scholar databases for relevant studies that were published between 1 January 1987 and 30 December 2019. A random effects meta-analysis model was used to estimate the pooled prevalence, odds ratios (ORs) and 95% confidence intervals (CIs). A total of 114 studies comprising 98 342 pregnant women across 35 countries were included in the systematic review and meta-analysis. Among IPIs identified from pregnant women, three helminth infections (hookworm 19% [95% CI 15 to 23], Ascaris lumbricoides 17% [95% CI 13 to 21] and Trichuris trichiura 11% [95% CI 7 to 16]) and three protozoan infections (Blastocystis sp. 21% [95% CI 4 to 46], Entamoeba histolytica/dispar 9% [95% CI 3 to 19] and Giardia sp. 8% [95% CI 4 to 13]) were identified as the most prevalent intestinal parasites. Moreover, we found that there was a significant association between IPIs with increased risk of anaemia in pregnant women (OR 2.65 [95% CI 2.08 to 3.37]). The prevalence of IPIs was slightly higher in geophagic pregnant women compared with controls, but this was not significant (OR 1.22 [95% CI 0.87 to 1.71]). According to species, the pooled OR of A. lumbricoides infection had a significantly higher risk in geophagic pregnant women compared with controls (OR 2.66 [95% CI 1.37 to 5.16]). There was a positive relationship between the high prevalence of IPIs in pregnant women living in rural areas compared with urban residents (OR 3.36 [95% CI 1.57 to 7.19]). The current review revealed a relatively high prevalence of IPIs in pregnant women, especially in some low- and middle-income countries. These results suggest a need for improved prevention and control efforts to reduce the health risks to pregnant women.